Search For "dcgi"
DCGI allows export of approx 2 lakh doses of Malaria vaccine
Updated : 3 years, 5 months ago IST
New Delhi [India], September 29 (ANI): The Drugs controller general of India (DCGI) allowed the export of approximately 2 lakh vaccine doses of Malaria which is produced in India, said sources on Thursday.
Read More
Bharat Biotech applies for market authorisation from DCGI for five arms in
Updated : 3 years, 6 months ago IST
New Delhi [India], September 11 (ANI): Bharat Biotech has applied for market authorisation from the Drugs Controller General of India (DCGI) for intranasal heterologous booster, sources told ANI.
Read More
Bharat Biotech-made iNCOVACC becomes world's first intranasal COVID vaccin
Updated : 3 years, 6 months ago IST
New Delhi [India], September 6 (ANI): The Drugs Controller General of India (DCGI) rendered an emergency use authorization (EUA) to Bharat Biotech for the intranasal vaccine- iNCOVACC, said officials on Tuesday.
Read More
COVID-19: India's first intranasal vaccine by Bharat Biotech gets DCGI app
Updated : 3 years, 6 months ago IST
New Delhi [India], September 6 (ANI): The Bharat Biotech on Tuesday got emergency use authorisation from the Drugs Controller General of India (DCGI) for the Intranasal Covid-19 vaccine.
Read More
Bombay HC issues notice to Central govt, Bill Gates, Serum Institute over
Updated : 3 years, 6 months ago IST
Mumbai (Maharashtra) [India] September 3 (ANI): The Bombay High Court issued notices to the Government of India, Serum Institute of India (SII), Microsoft founder Bill Gates, All India Institute of Medical Science Director, DCGI chief and others after a petition was filed by father of a l
Read More
DCGI chief Venugopal Somani's tenure extended by 3 months
Updated : 3 years, 6 months ago IST
New Delhi [India], August 17 (ANI): The tenure of Dr V G Somani as the Drugs Controller General of India (DCGI) has been extended by three months, according to an order issued by the Union Health Ministry.
Read More
Corbevax heterologous COVID-19 booster expected to get final approval from
Updated : 3 years, 7 months ago IST
New Delhi [India], August 9 (ANI): The Union Government is considering giving its final approval to Corbevax's heterologous COVID-19 booster for 'Restricted Use in Emergency Situation' soon, sources said.
Read More
DCGI approves India's first qHPV vaccine to treat cervical cancer
Updated : 3 years, 8 months ago IST
New Delhi [India], July 12 (ANI): India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer gets Drugs Controller General of India (DCGI) approval for market authorisation. This vaccine will be manufactured by the Serum Institute of India (SII).
Read More
If govt permits indigenous mRNA vaccine is ready to be roll out in 72 hou
Updated : 3 years, 8 months ago IST
New Delhi [India], June 29 (ANI): The company is ready to roll out India's first mRNA vaccine in 72 hours after the government's permission, said Gennova Biopharmaceuticals Ltd Chief Executive Officer and Whole-time Director Dr Sanjay Singh.
Read More
India's first mRNA vaccine by Gennova gets DCGI approval, to be rolled out
Updated : 3 years, 8 months ago IST
Pune (Maharashtra) [India], June 29 (ANI): India's first indigenously developed mRNA vaccine against the COVID-19 gets the Emergency Use Authorization (EUA), to be sold under the brand name GEMCOVAC™-19 and will be rolled out soon, informed the officials on Wednesday.
Read More
SII's Covovax gets DCGI emergency use nod for children between 7-12 years
Updated : 3 years, 8 months ago IST
New Delhi [India], June 28 (ANI): The Drugs Controller General of India (DCGI) has given restricted emergency use authorisation (EUA) to Pune-based Serum Institute of India's COVID-19 vaccine 'Covovax' for children aged 7 to 12 years, sources told ANI.
Read More
DCGI gives emergency use authorisation to India's first mRNA COVID-19 vacc
Updated : 3 years, 8 months ago IST
New Delhi [India], June 28 (ANI): The Drugs Controller General of India (DCGI) has approved two doses of Pune-based Gennova Biopharmaceuticals' mRNA COVID-19 vaccine for restricted use in emergency situations for beneficiaries aged above 18 years age group.
Read More